This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GSK3B / Glycogen synthase kinase-3 beta · Western blot design guide
Design a Western Blot for GSK3B
Real validated GSK3B Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-GSK3B WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
GSK3B Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~46.7 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Caudate (total-target IHC; phospho state unverified) +4 more | |
| Negative control | Adipose tissue (total-target IHC; phospho state unverified) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated | |
| Caveat | Activation-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 2 isoform(s) |
Section 1
Real Curated GSK3B Western Blot Protocols
The P00791-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | 293T cell lysates, treated with Calyculin A (catalog P00791-1) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% BSA in TBST (standard starting point) |
| Primary antibody | P00791-1; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected GSK3B Western Blot Band Size?
GSK3B is predicted at 46.7 kDa, with no empirical band size supplied; isoforms may affect migration, while the lead antibody detects only Ser9-phosphorylated protein.
| Band near 46.7 kDa | Consistent with predicted GSK3B size; confirm identity with controls |
| Band in a phospho-Ser9 blot | Recognized GSK3B carries the Ser9 phosphorylation targeted by the lead antibody |
| No phospho-Ser9 band despite a total GSK3B band | GSK3B may be present without detectable Ser9 phosphorylation |
| Multiple bands near the expected region | Isoforms 1 and 2 are possible contributors, but distinct migration is unestablished |
💡Expected GSK3B appearanceUniProt predicts 46.7 kDa for GSK3B; no empirical band size is supplied, and the lead antibody detects the Ser9-phosphorylated state, so confirm band identity with total GSK3B and specificity controls.
| UniProt predicted mass | Sets a 46.7 kDa reference, not a measured migration position |
| Isoform 1 | May differ in size from isoform 2; its mass is not supplied |
| Isoform 2 | May differ in size from isoform 1; its mass is not supplied |
| Alternative splicing into isoforms 1 and 2 | Could affect apparent size, but distinct bands are not established |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | The Ser9-phosphorylated state may be below detection | Check total GSK3B and compare with a phosphatase-inhibited sample |
| Band higher than expected | An isoform or an unrelated antibody signal is possible; the cause is unestablished | Compare total GSK3B and verify antibody specificity |
| Band lower than expected | An isoform or an unrelated antibody signal is possible; the cause is unestablished | Check antibody specificity and compare with total GSK3B |
| Multiple bands | Isoforms 1 and 2 or unrelated antibody signals may contribute | Compare with total GSK3B and use an isoform-specific control if available |
| Weak or no signal | Low Ser9 phosphorylation may limit binding by the phospho-specific antibody | Check total GSK3B and compare with a calyculin A-treated sample |
Experiment evidence
Western blot images showing GSK3B band
P00791-1 · GSK3B
A00791-3 · GSK3B
M00791 · GSK3B
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for GSK3B Western blot
🧪HPA-IHC candidate guidance (verify in WB): HPA tissue expression does not establish phosphorylation at the selected antibody epitope. Verify activation-state controls for the phospho-specific lead. HPA-IHC candidate guidance (verify in WB): For positive controls for GSK3B in Western blot, you can use caudate tissue lysate, which HPA scores high.
Positive control: Caudate (total-target IHC; phospho state unverified)
Negative control: Adipose tissue (total-target IHC; phospho state unverified)
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: HPA lists adipose tissue as not detected, but confirm its negative signal in your lysate.
HPA tissue expression evidence for GSK3B
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Caudate | neuronal cells | High | Protein (IHC) | HPA → |
| Cerebellum | cells in molecular layer | High | Protein (IHC) | HPA → |
| Cerebral cortex | neuronal cells | High | Protein (IHC) | HPA → |
| Hippocampus | neuronal cells | High | Protein (IHC) | HPA → |
| Appendix | glandular cells | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Lung | alveolar cells | Not detected | Protein (IHC) | HPA → |
| Skeletal muscle | myocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced GSK3B Western Blot Tips
Deeper troubleshooting and optimisation questions for GSK3B, answered from its protein features.
Where should the main GSK3B band appear?
Band shift · The canonical sequence predicts 46.7 kDa. No empirical apparent band is supplied, so use 46.7 kDa as a reference rather than an exact migration position. The listed modifications alone do not establish a visible shift.
Could GSK3B isoforms produce different bands?
Isoforms · UniProt lists two isoforms. In isoform 2, canonical residue 303 changes from K to KDSSGTGHFTSGVR. This sequence difference could affect migration, but the features do not establish distinct visible bands.
Which GSK3B phosphorylation sites are listed?
PTM · UniProt lists Ser9, Tyr216, Ser389, Thr390 and Thr402. These are supplied UniProt coordinates; check the numbering convention used by any antibody or paper before comparing site labels.
The Ser9 feature names PKB/AKT1, RPS6KA3, SGK3 and NME7. It does not specify an induction condition or show that any one enzyme acted in a particular sample.
Compare a site-specific phospho signal with total GSK3B from matched samples, and state which UniProt site was measured. The listed sites are Ser9, Tyr216, Ser389, Thr390 and Thr402; total protein signal alone cannot distinguish their phosphorylation states.
The Ser9 feature names PKB/AKT1, RPS6KA3, SGK3 and NME7. It does not specify an induction condition or show that any one enzyme acted in a particular sample.
Compare a site-specific phospho signal with total GSK3B from matched samples, and state which UniProt site was measured. The listed sites are Ser9, Tyr216, Ser389, Thr390 and Thr402; total protein signal alone cannot distinguish their phosphorylation states.
Does this guide establish induction of GSK3B?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for GSK3B?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the P00791-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should GSK3B be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
How should unexpected GSK3B bands be interpreted?
Interpretation · Consider the isoform 2 sequence change at residue 303 and the five listed phosphorylation sites when investigating additional bands. Neither feature establishes that an extra band is GSK3B or proves a visible mass shift; verify band identity before assigning a cause.
GSK3B is listed in the cytoplasm, nucleus and cell membrane. A fraction-specific blot may therefore show a different signal from a whole-cell sample. Record which fraction was loaded when comparing band intensity.
GSK3B is listed in the cytoplasm, nucleus and cell membrane. A fraction-specific blot may therefore show a different signal from a whole-cell sample. Record which fraction was loaded when comparing band intensity.
Boster reagents
GSK3B Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-Phospho-GSK3 beta (Ser9) Rabbit Monoclonal Antibody
Cat # P00791-1
Real WB data
Anti-GSK3 beta/GSK3B Antibody Picoband®
Cat # A00791-3
Real WB data
Anti-GSK3 beta Rabbit Monoclonal Antibody
Cat # M00791
Three listed antibodies have WB images: one detects phospho-GSK3 beta (Ser9), while two detect GSK3 beta. The supplied evidence consists of product reactivity and example blots; these images show performance in the stated lysates and conditions only.
Which to pick: Choose P00791-1 for phospho-Ser9 in human samples; its image uses Calyculin A-treated 293T lysate. For total GSK3 beta, A00791-3 lists human, mouse, and rat reactivity with blots from each; M00791 lists human and mouse reactivity, though its blot also includes rat lysates.
Source: BosterBio GSK3B gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P49841.
- Human Protein Atlas. GSK3B tissue expression.
- PMC3797167 — target-verified WB comparison
- PMC11338547 — target-verified WB comparison
- PMC12010908 — target-verified WB comparison